PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification (Form PCT/ISA	of Transmittal of International Search Report (220) as well as, where applicable, item 5 below.			
2973 ACTION					
International application No.	International filing date(day/month/year)	(Earliest) Priority Date (day/month/year)			
PCT/US 97/03347	11/03/1997	11/03/1996			
Applicant					
ANEDTOAN DIO MEDICA CODDO	DATTON -4 -1	·			
AMERICAN BIO MEDICA CORPO	RAIIUN et al.				
This International Search Report has be according to Article 18. A copy is being	en prepared by this International Searching A transmitted to the International Bureau.	uthority and is transmitted to the applicant			
This International Search Report consist X It is also accompanied by a cop	s of a total of 4 sheets. by of each prior art document cited in this rep	ort.			
1. Certain claims were found unse	archable (see Box I).				
2. Unity of invention is lacking (se	e Box II).				
3. The international application of international search was carried	ontains disclosure of a nucleotide and/or amino d out on the basis of the sequence listing	o acid sequence listing and the			
	d with the international application.				
fur	nished by the applicant separately from the in				
·	but not accompanied by a statement to matter going beyond the disclosure in the	the effect that it did not include ne international application as filed.			
Tra	anscribed by this Authority				
4. With regard to the title, X the	text is approved as submitted by the applican	at.			
the	text has been established by this Authority to	o read as follows:			
5. With regard to the abstract,	e text is approved as submitted by the applica	nt			
X the	e text has been established, according to Rule in III. The applicant may, within one month farch Report, submit comments to this Author	38.2(b), by this Authority as it appears in rom the date of mailing of this International			
6. The figure of the drawings to be put	olished with the abstract is:				
· _	suggested by the applicant.	None of the figures.			
ber	cause the applicant failed to suggest a figure.				
be-	cause this figure better characterizes the inven	tion.			

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61B10/00 B01L3/00

G01N33/543

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{lll} \mbox{Minimum documentation searched} & \mbox{(classification system followed by classification symbols)} \\ \mbox{IPC 6} & \mbox{B01L} & \mbox{A61B} & \mbox{G01N} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 119 830 A (DAVIS RICHARD C) 9 June 1992 see the whole document	1,3,5
A .	US 5 368 583 A (FLEURY RICHARD) 29 November 1994 see column 4, line 59 - column 6, line 23	1,3
Α .	US 5 352 410 A (HANSEN WARREN D ET AL) 4 October 1994 see column 13, line 24 - column 16, line 34; figures 5-8	1,3
A	WO 95 07659 A (HOFFMANN LA ROCHE) 23 March 1995 see page 6, line 1 - page 9, line 19 	1,3,5

X Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to
"L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
27 June 1997	2 3. 07. 97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Bindon, C

Form PCT/ISA/210 (second sheet) (July 1992)

1

		PC1/03 37	703347
C.(Continue	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
A	EP 0 634 215 A (BOEHRINGER MANNHEIM GMBH) 18 January 1995 see column 2, line 31 - column 6, line 21; figures 3,4		5
A .	WO 94 06940 A (ABBOTT LAB) 31 March 1994 see page 3, line 34 - line 37	•	5
A	US 4 873 193 A (JENSEN RICHARD E ET AL) 10 October 1989 see the whole document		1-3
A	FR 2 581 194 A (MATERIEL BIOMEDICAL) 31 October 1986 see abstract; figures		1,3

1

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5119830 A	09-06-92	AU 1772692 A WO 9217109 A	02-11-92 15-10-92
US 5368583 A	29-11-94	DE 4429885 A GB 2292606 A	07-03-96 28-02-96
US 5352410 A	04-10-94	US 5523055 A	04-06-96
WO 9507659 A	23-03-95	US 5403551 A AU 7695994 A CA 2147498 A CN 1114495 A EP 0668745 A JP 8503556 T NZ 273604 A	04-04-95 03-04-95 23-03-95 03-01-96 30-08-95 16-04-96 28-10-96
EP 0634215 A	18-01-95	DE 4323672 A JP 7077525 A US 5556789 A	19-01-95 20-03-95 17-09-96
WO 9406940 A	31-03-94	AU 4925993 A	12-04-94
US 4873193 A	10-10-89	US 4917867 A US 5186900 A	17-04-90 16-02-93
FR 2581194 A	31-10-86	NONE	



rnational application No.

PCT/US 97/03347

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

A drug abuse test kit has a transparent cup-like container (1) for retaining a fluid sample to be tested and the open top end (14) of the container (11) is closed by a closure cap (22) seated upon the open end (14). There is a slit (19) in the closure cap (22) to receive a multiple drug test card (25) having a plurality of immunoassay test strips thereon with visual endpoints to indicate presence or absence of a particular drug. The container (11) is provided with a second cover (15) which is solid and unslit to close and seal the container (11) when a sample therein is to be transported.

For receiving Office use only International Application No. REQUEST International Filing Date The undersigned requests that the present international application be processed Name of receiving Office and "PCT International Application" according to the Patent Cooperation Treaty. Applicant's or agent's file reference (if desired) (12 characters maximum) TITLE OF INVENTION DEVICE FOR THE COLLECTION, TESTING AND Box No. I SHIPMENT OF BODY FLUID SAMPLES APPLICANT Box No. II Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.) This person is also inventor. Telephone No American Bio Medica Corporation 518-329-4490 102 Simons Road Facsing 8 No 329 - 4156 Ancramdale, New York 12503 U.S.A. Teleprinter No. A corporation of the State of New York State (i.e. country) of residence: State (i.e. country) of nationality: U.S.A. U.S.A. the States indicated in the Supplemental Box the United States of America only all designated States except the United States of America This person is applicant all designated for the purposes of:

FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.)

Ancramdale, New York 12503

all designated States

The person identified below is hereby/has been appointed to act on behalf

of the applicant(s) before the competent International Authorities as:

Further applicants and/or (further) inventors are indicated on a continuation sheet.

Name and address: tFamily name followed by given name: for a legal entity. full official designation. The address must include postal code and name of country.)

JASKIEWICZ, Edmund M.

1730 M Street NW
Suite 400
Washington, D.C. 20036
U.S.A.
U.S. Pat. & TM. Off. Reg.No. 17875

Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

all designated States except the United States of America

AGENT OR COMMON REPRESENTATIVE: OR ADDRESS FOR CORRESPONDENCE

CIPKOWSKI, Stan 102 Simons Road

U.S.A.

State (i.e. country) of nationality:

U.S.A.

This person is applicant for the purposes of:

Box No. IV

Box No. III

This person is:

State (i.e. country) of residence:

U.S.A.

the United States of America only

agent

applicant only

applicant and inventor

inventor only (If this check-box is marked, do not fill in below.)

the States indicated in the Supplemental Box

common representative

Box	No.V	DESIGNATION OF STATES					
The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes: at least one must be marked):							
Regional Patent							
_			vi SI) Suda	n, SZ Swaziland, UG Uganda, and any other State which		
×	, ,,,	is a Contracting State of the Harare Protocol and of t	he P	CT	in, 62 3 wazimino, 66 ogainat, and any other state winer		
X							
X	EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT						
OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT tif other kind of protection or treatment desired, specify on dotted line)							
Natio	ona' P	atent tif other kind of protection or treatment desired,	spec	ify on	dotted liner:		
Г		Albania		LU	Luxembourg		
\vdash	AM	Armenia		LV	Latvia		
×	AT	Austria		MD	Republic of Moldova		
×	AU	Australia		MG	Madagascar		
一		Azerbaijan	$\bar{\sqcap}$		The former Yugoslav Republic of Macedonia		
$\overline{\Gamma}$		Bosnia and Herzegovina	_				
	BB	Barbados	\Box	MN	Mongolia		
\vdash	BG	Bulgaria	$\overline{\Box}$		Malawi		
X	,	Brazil	ĸ	MX	Mexico		
F	BY	Belarus	X		Norway		
X	•	Canada	X		New Zealand		
×	,	and LI Switzerland and Liechtenstein	M	PL	Poland		
X	,	China	H	PT	Portugal		
	,	Cuba	H	RO	Romania		
įX.		Czech Republic	쩝		Russian Federation		
X X	•	Germany	M	RU	Sudan		
<u> </u>	•	Denmark	님	SD	Sundan Sundan		
닏		Estonia		SE	Sweden		
느	EE		K	SG	Singapore		
느	ES	Spain	K	SI	Slovenia		
	FI	Finland	Ш	SK	Slovakia		
	,	United Kingdom		TJ	Tajikistan		
		Georgia		TM	Turkmenistan		
	HU	Hungary		TR	Turkey		
	IL	Israel	\Box	TT	Trinidad and Tobago		
	IS	Iceland		UA	Ukraine		
X	JP	Japan		UG	Uganda		
	,	Kenya		US	United States of America		
] KG	Kyrgyzstan		•	Continuation-in-part		
	KP	Democratic People's Republic of Korea		$\mathbf{U}\mathbf{Z}$	Uzbekistan		
			凶	VN	Viet Nam		
	KR	Republic of Korea	C L	1. 1	xes reserved for designating States (for the purposes of		
	KZ	Kazakstan	a na	itional	patent) which have become party to the PCT after		
] LC	Saint Lucia			of this sheet:		
	,	Sri Lanka					
· C] LR	Liberia					
] LS	Lesotho					
] LT	Lithuania					
unde	or the P	CT except the designation(s) of			r Rule 4.9(b) all designations which would be permitted		
The	applier	int declares that those additional designations are subjected	ect to	conti	mation and that any designation which is not confirmed		
befo	re the e	expiration of 15 months from the priority date is to be r	egar	ued as	withdrawn by the applicant at the expiration of that time lesignation and the payment of the designation and confirmation		
umi	i. (Confi	irmation of a designation consists of the fitting of a notice spe	-yym	5 mui (resignation and the payment of the assignment and sorigination		

If the Supplemental Box is not used, this sheet need not be included in the request.

Use this box in the following cases:

1. If, in any of the Boxes, the space is insufficient to furnish all the information:

in particular:

- (i) if more than two persons are involved as applicants and or inventors and no "continuation sheet" is available:
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked:
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America:
- (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents:
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "Continuation" or "Continuationin-part":
- (vi) if there are more than three earlier applications whose priority is claimed:
- 2. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty:

in such case, write "Continuation of Box No. ..." findicate the number of the Box | and furnish the information in the same manner as required according to the cuptions of the Box in which the space was insufficient;

in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below:

in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. III and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and or, where applicable, ARIPO, Eurasian, European or OAPI patents for the purposes of which the named person is applicant:

in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Loxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;

in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;

in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;

in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.

in such case, write "Statement Concerning Non-Prejudicial Disclosures or Exceptions to Lack of Novelty" and furnish that statement below.

Continuation of Box V
Parent application for U.S.A. designation
U.S.A. 11 March 1996 Application no. 08/613,487

Sheet No. 9/1.

Box No. VI PRIORITY CLAIM Further priority claims are indicated in the Supplemental Box						
The priority of the following earlier application(s) is hereby claimed:						
Country (in which, or for which, the application was filed)		ng Date onth/year)	Application No.	Office of filing (only for regional or international application)		
item (1) U.S.A.	ll Mar	ch 1996	08/613,487	·		
item (2)						
item (3)						
Mark the following check-box if the capplication is the receiving Office (a) The receiving Office is he Bureau a certified copy o	<i>fee may be required</i> ereby requested t	<i>0:</i> o prepare and trans	mit to the International	the purposes of the present international 1		
Box No. VII INTERNATIO	NAL SEARCH	ING AUTHORITY	·			
Choice of International Searce are competent to carry out the intern	national search. inc	licate the Authority ch	osen; the two-letter code may be use	cities ed): ISA / EPO ing Authority has already been carried		
out or requested and the Authority is such search or request either by refu Country (or regional Office):	now requested to erence to the relev	base the international	search, to the extent possible, on th	e results of that earlier search. Identify ce to the search request:		
Box No. VIII CHECK LIST						
This international application contains the following number of sheets: 1. request : 4 sheets 2. description : 1.5 sheets 3. claims : 4 sheets 4. abstract : 1 sheets 5. drawings : 5 sheets Total : 2.9 sheets Figure No. 1 of the drawings (if any) should accompany the abstract when it is published. Box No. IX SIGNATURE OF APPLICANT OR AGENT Next to each signature, indicate the name of the person signing and the ordinary in which the person signs if such capacity is not obvious from reading the request). This international application is accompanied by the item(s) marked below: 1. X separate signed power of attorney 5. X fee calculation sheet 6. Separate indications concerning deposited microorganisms 7. Includentified in Box No. VI as item(s): 4. Includentified in Box No. VI as item(s): 5. X fee calculation sheet 6. Includentified in Box No. VI as item(s): 6. Includentified in Box No. VI as item(s): 8. Includentified in Box No. VI as item(s):						
Date of actual receipt of the international application:	purported	— For receiving (Office use only	2. Drawings:		
Corrected date of actual received papers or drug the purported international actual received papers.	awings completi	out ng		received:		
Date of timely receipt of the corrections under PCT Artic	required :le 11(2):			not received:		
International Searching Authorities by the applicant:	ority ISA /	6.	Transmittal of search countil search fee is paid	py delayed		
Date of receipt of the record co		• For International	Bureau use only			

PCT	For receiving Office use only
FEECALCULATIONSHEET Annex to the Request	International application No.
Applicant's or agent's 1973	Date stamp of the receiving Office
Applicant American Bio Medica Corporatio 102 Simons Road Ancramdale, New York 12503	u.s.A.
CALCULATION OF PRESCRIBED FEES	
I. TRANSMITTAL FEE	230.00 T
2. SEARCH FEE International search to be carried out by EPO (If two or more International Searching Authorities are competent in relation application, indicate the name of the Authority which is chosen to carry out the fin	
3. INTERNATIONAL FEE	
Basic Fee The international application contains 29 sheets.	
first 30 sheets	.00 b ₁
remaining sheets additional amount	
Add amounts entered at b ₁ and b ₂ and enter total at B	590.00 B
Designation Fees The international application contains 24 designations.	<u> </u>
11 x 143.00 =	1573.00 D
number of designation fees amount of designation fee payable (maximum 11)	
Add amounts entered at B and D and enter total at I (Applicants from certain States are entitled to a reduction of 75% of th international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.	· · · · · · · · · · · · · · · · · · ·
4. FEE FOR PRIORITY DOCUMENT	15.00 P
5. TOTAL FEES PAYABLE Add amounts entered at T, S, I and P, and enter total in the TOTAL be	ox \$ 3993.00 US
	TOTAL
The designation fees are not paid at this time.	·
MODE OF PAYMENT	
authorization to charge deposit account (see below) cheque postal money order bank draft x cash revenue stamps	coupons other (specify):
DEPOSIT ACCOUNT AUTHORIZATION (this mode of payment me	ay not be available at all receiving Offices)
The RO/ is hereby authorized to charge the total fees in	ndicated above to my deposit account.
deposit account.	y or credit any overpayment in the total fees indicated above to my
is hereby authorized to charge the fee for prep Bureau of WIPO to my deposit account.	paration and transmittal of the priority document to the International

Signature

Deposit Account Number

Date (day month year)

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s) (Family name followed by given name; for a legal entity, for	ll official designation. The address must include postal code and name of	country.)
American Bio Medica Cor 102 Simons Road Ancramdale, New York 12 U.S.A.		
A corporation of the St	ate of New York	
hereby appoints (appoint) the following person as:	agent common representative	
Name and address (Family name followed by given name; for a legal entity, full c	fficial designation. The address must include postal code and name of cou	intry.)
JASKIEWICZ, Edmund M. 1730 M Street NW Suite 400 Washington, D.C. 20036 U.S.A.	U.S.A. Patent & Trademark Office Registration No. 17875	
to represent the undersigned before	all the competent International Authorities	
•	the International Searching Authority only	
	the International Preliminary Examining Authority onl	У
in connection with any and all international application	s filed by the undersigned with the following Office	
U.S.A.	as receiving	ng Office
and to make or receive payments on behalf of the unde	rsigned.	
Signatures of the applicant(s) (where there are several applic the capacity in which the perso	ants, each of them must sign; next-to-each signature, indicate the name of the person in signs, if such capacity is not obvious from reading the request or this-power)	signing and
·		
American Bio Medica Cor	p.	
Mar	ch 7, 1997	
Stan CIPKOWSKI , Presid		
5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		